Representative before the EPO

Technology company logo thumb
no operation time available
1 office
Technology Company

Henrik Skødt has worked on the following 2 EPO patent applications which have been published in the last five years:

EP12705608

mTOR/JAK INHIBITOR COMBINATION THERAPY

IPC classification:
A61K 31/436, A61K 31/519, A61P 35/00
Applicant:
Novartis Pharma AG
Agent:
Zöe Clyde-Watson, D Young & Co LLP
Agent:
Multiple attorneys, Novartis Pharma AG
Status:
The patent has been granted
EP12173896

Ophthalmic compositions containing a synergistic combination of two polymers

IPC classification:
A61K 9/08, A61K 47/36, A61K 47/38
Applicant:
Novartis AG
Agent:
Stephan Teipel, Lederer Keller Patentanwälte Partnerschaft mbB
Agent:
Henrik Skødt, Novartis Pharma AG
Status:
PATENT GRANTED

Please Sign in to use this feature